These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 32824655)

  • 21. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
    Cao Y; Li W; Wang Z; Pang H
    Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.
    Jiang W; Pan S; Chen X; Wang ZW; Zhu X
    Mol Cancer; 2021 Sep; 20(1):116. PubMed ID: 34496886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
    Ayala-Mar S; Donoso-Quezada J; González-Valdez J
    J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
    Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
    Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
    Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
    Front Immunol; 2020; 11():563258. PubMed ID: 33488573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy.
    Salmaninejad A; Valilou SF; Shabgah AG; Aslani S; Alimardani M; Pasdar A; Sahebkar A
    J Cell Physiol; 2019 Aug; 234(10):16824-16837. PubMed ID: 30784085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments.
    Jachetti E; Sangaletti S; Chiodoni C; Ferrara R; Colombo MP
    Cell Immunol; 2021 Apr; 362():104301. PubMed ID: 33588246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.
    Liang B; Hu X; Ding Y; Liu M
    J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy.
    Yu L; Huang K; Liao Y; Wang L; Sethi G; Ma Z
    Cell Prolif; 2024 Aug; 57(8):e13644. PubMed ID: 38594879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers associated with checkpoint inhibitors.
    Manson G; Norwood J; Marabelle A; Kohrt H; Houot R
    Ann Oncol; 2016 Jul; 27(7):1199-206. PubMed ID: 27122549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy.
    Escors D; Bocanegra A; Chocarro L; Blanco E; Piñeiro-Hermida S; Garnica M; Fernandez-Rubio L; Vera R; Arasanz H; Kochan G
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
    Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
    Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
    Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.